See up to 3 months of CRIS. The 7-day demo opens the 1M and 3M ranges and puts CRIS on your watchlist.
Start 7-day demoLatest CRIS insider trades
About CURIS INC (CRIS)
CURIS INC files with the SEC under CIK 0001108205 and is classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site. It filed a registration statement with the SEC on 10 August 2026 and has not yet priced an offering.
CRIS Form 4 activity by transaction type, last 90 days
No Form 4 activity for CRIS in the last 90 days.
CRIS insider transactions (Form 4)
4828 Form 4 filings on record, the earliest from May 1, 2025, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Marc Rubin - Director | Grant or award | Non Qualified Stock Option | 6,800 | $5.29 | $36K | |
| Kenneth I. Kaitin - Director | Grant or award | Non Qualified Stock Option | 6,800 | $5.29 | $36K | |
| John Hohneker - Director | Grant or award | Non Qualified Stock Option | 6,800 | $5.29 | $36K | |
| Martyn D. Greenacre - Director | Grant or award | Non Qualified Stock Option | 6,800 | $5.29 | $36K | |
| Anne Elizabeth Borgman - Director | Grant or award | Non Qualified Stock Option | 6,800 | $5.29 | $36K | |
| Diantha Duvall - Officer | Grant or award | Employee stock option (right to buy) | 48,285 | $5.29 | $255K | |
| Jonathan B. Zung - Officer | Grant or award | Employee stock option (right to buy) | 48,285 | $5.29 | $255K | |
 James E. Dentzer - Officer | Grant or award | Employee stock option (right to buy) | 110,090 | $5.29 | $582K | |
| Kenneth I. Kaitin - Director | Open-market purchase | Common Stock | 10,000 | $0.55 | $5K | |
| Jonathan B. Zung - Officer | Other | Common Stock | 66,667 | - footnote F1 | - | |
| Jonathan B. Zung - Officer | Other | Series B Convertible Preferred Stock | 50 | - footnote F1 | - | |
| ||||||
| Ahmed Md Hamdy - Officer | Other | Common Stock | 66,667 | - footnote F1 | - | |
| Ahmed Md Hamdy - Officer | Other | Series B Convertible Preferred Stock | 50 | - footnote F1 | - | |
| ||||||
| Diantha Duvall - Officer | Other | Common Stock | 66,666 | - footnote F1 | - | |
| Diantha Duvall - Officer | Other | Series B Convertible Preferred Stock | 50 | - footnote F1 | - | |
| ||||||
| James E. Dentzer - Officer | Other | Common Stock | 133,333 | - footnote F1 | - | |
| James E. Dentzer - Officer | Other | Series B Convertible Preferred Stock | 100 | - footnote F1 | - | |
| ||||||
| Marc Rubin - Director | Other | Common Stock | 26,667 | - footnote F1 | - | |
| Marc Rubin - Director | Other | Series B Convertible Preferred Stock | 20 | - footnote F1 | - | |
| ||||||
| Jonathan B. Zung - Officer | Grant or award | Series B Convertible Preferred Stock | 50 | - footnote F2 | - | |
| Jonathan B. Zung - Officer | Grant or award | Series A Warrant (right to buy) | 66,667 | - footnote F2 | - | |
| Jonathan B. Zung - Officer | Grant or award | Series B Warrant (right to buy) | 66,667 | - footnote F2 | - | |
| Jonathan B. Zung - Officer | Grant or award | Series C Warrant (right to buy) | 66,667 | - footnote F2 | - | |
| ||||||
| Ahmed Md Hamdy - Officer | Grant or award | Series B Convertible Preferred Stock | 50 | - footnote F2 | - | |
| Ahmed Md Hamdy - Officer | Grant or award | Series A Warrant (right to buy) | 66,667 | - footnote F2 | - | |
| Ahmed Md Hamdy - Officer | Grant or award | Series B Warrant (right to buy) | 66,667 | - footnote F2 | - | |
| Ahmed Md Hamdy - Officer | Grant or award | Series C Warrant (right to buy) | 66,667 | - footnote F2 | - | |
| ||||||
| Diantha Duvall - Officer | Grant or award | Series B Convertible Preferred Stock | 50 | - footnote F2 | - | |
| Diantha Duvall - Officer | Grant or award | Series A Warrant (right to buy) | 66,666 | - footnote F2 | - | |
| Diantha Duvall - Officer | Grant or award | Series B Warrant (right to buy) | 66,666 | - footnote F2 | - | |
| Diantha Duvall - Officer | Grant or award | Series C Warrant (right to buy) | 66,666 | - footnote F2 | - | |
| ||||||
| James E. Dentzer - Officer | Grant or award | Series B Convertible Preferred Stock | 100 | - footnote F2 | - | |
| James E. Dentzer - Officer | Grant or award | Series A Warrant (right to buy) | 133,333 | - footnote F2 | - | |
| James E. Dentzer - Officer | Grant or award | Series B Warrant (right to buy) | 133,333 | - footnote F2 | - | |
| James E. Dentzer - Officer | Grant or award | Series C Warrant (right to buy) | 133,333 | - footnote F2 | - | |
| ||||||
| Marc Rubin - Director | Grant or award | Series B Convertible Preferred Stock | 20 | - footnote F2 | - | |
| Marc Rubin - Director | Grant or award | Series A Warrant (right to buy) | 26,667 | - footnote F2 | - | |
| Marc Rubin - Director | Grant or award | Series B Warrant (right to buy) | 26,667 | - footnote F2 | - | |
| Marc Rubin - Director | Grant or award | Series C Warrant (right to buy) | 26,667 | - footnote F2 | - | |
| ||||||
| James E. Dentzer - Officer | Grant or award | Employee stock option (right to buy) | 360,000 | $3.13 | $1.13M | |
| John Hohneker - Director | Grant or award | Non Qualified Stock Option | 14,400 | $3.13 | $45K | |
| Martyn D. Greenacre - Director | Grant or award | Non Qualified Stock Option | 14,400 | $3.13 | $45K | |
| Marc Rubin - Director | Grant or award | Non Qualified Stock Option | 14,400 | $3.13 | $45K | |
| Diantha Duvall - Officer | Grant or award | Employee stock option (right to buy) | 135,000 | $3.13 | $423K | |
| Anne Elizabeth Borgman - Director | Grant or award | Non Qualified Stock Option | 14,400 | $3.13 | $45K | |
| Jonathan B. Zung - Officer | Grant or award | Employee stock option (right to buy) | 135,000 | $3.13 | $423K | |
| Kenneth I. Kaitin - Director | Grant or award | Non Qualified Stock Option | 14,400 | $3.13 | $45K | |
| Ahmed Md Hamdy - Officer | Grant or award | Employee stock option (right to buy) | 200,000 | $2.48 | $496K | |
Item 3.01
Item 3.03, 5.03, 9.01
Item 5.03
Item 5.03
CRIS insider trading FAQ
What is the latest insider trade for CRIS?
CURIS INC (CRIS) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-09. The full record for CRIS runs to 28 Form 4 filings, the earliest from 2025-05-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying CRIS stock?
No insider purchases of CRIS were filed in the last 90 days. 1 purchase is on record for this company.
How many insiders are selling CRIS stock?
No insider sales of CRIS were filed in the last 90 days.
Where can I see CRIS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects CRIS Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Marc Rubin view on EDGAR
- - Kenneth I. Kaitin view on EDGAR
- - John Hohneker view on EDGAR
- - Martyn D. Greenacre view on EDGAR
- - Anne Elizabeth Borgman view on EDGAR
- - Diantha Duvall view on EDGAR
- - Jonathan B. Zung view on EDGAR
- - James E. Dentzer view on EDGAR
- - Kenneth I. Kaitin view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Insider activity in Health Care
- Where CRIS's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow CRIS with a 7-day demo
- CRIS on your watchlist
- Every CRIS Form 4 filing on record
- Up to 3 months of CRIS price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
